Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Post-study crossover and exposure time bias: A limited analysis of the pyrotinib HER2-positive breast cancer trial Through controlled trials of pyrotinib or placebo versus trastuzumab and docetaxel, this article reveals that the pyrotinib group is superior to the placebo group in maintaining longer progression-free survival and improving overall survival in the initial treatment of HER2-positive metastatic breast cancer.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
